Zdrowie i gospodarka · 18.07.2014
Draft Guidance for Industry: Providing Submissions in Electronic Format-Postmarketing Safety Reports for Vaccines; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft document entitled "Guidance for Industry: Providing Submissions in Electronic Format--Postmarketing Safety Reports for Vaccines" dated July 2014. The draft guidance document provides information and recommendations pertaining to the electronic submission of postmarketing safety reports involving vaccine products marketed for human use with approved biologics license applications (BLAs), including individual case safety reports (ICSRs) and attachments to ICSRs (ICSR attachments), into the Vaccine Adverse Event Reporting System (VAERS). FDA recently published in the Federal Register a final rule requiring that certain postmarketing safety reports for human drug and biological products, including vaccines, be submitted to FDA in an electronic format that the Agency can process, review, and archive. The draft guidance, when finalized, is intended to help applicants required to submit postmarketing safety reports comply with the final rule. The draft guidance, when finalized, also will supersede the document entitled "Guidance for Industry: How to Complete the Vaccine Adverse Event Report System Form (VAERS